Experimental drug shows promise for tough bone cancers
NCT ID NCT02243605
First seen Mar 13, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This phase 2 trial tests the drug cabozantinib in 90 patients with osteosarcoma or Ewing sarcoma that has returned or spread. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. The main goal is to see if the cancer stops growing or shrinks within six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT EWING SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU Strasbourg - Hospital Civil
Strasbourg, 67091, France
-
Center Claudius Regaud
Toulouse, 31052, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Georges-Francois Leclerc
Dijon, 21079, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambert
Lille, 59020, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hopital De La Timone
Marseille, 13385, France
-
Institut Bergonie Cancer Center
Bordeaux, 33076, France
-
Institut Curie Paris
Paris, 75005, France
-
Institut de Cancerologie de l'Ouest-Rene Gauducheau
Saint-Herblain, 44805, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabozantinib (a drug that blocks enzymes needed for cancer cell growth and prevents new blood vessel formation)
What this could lead to
If successful, this could provide a new treatment option for patients with relapsed osteosarcoma or Ewing sarcoma, potentially slowing or stopping tumor growth.
What could go wrong
This is a mid-stage trial with only 90 participants, so results may not apply to all patients. The drug may cause side effects and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.